Reuters logo
BRIEF-Fibrogen's ‍Pamrevlumab was well tolerated with no safety risks
September 13, 2017 / 11:33 AM / 12 days ago

BRIEF-Fibrogen's ‍Pamrevlumab was well tolerated with no safety risks

Sept 13 (Reuters) - Fibrogen Inc

* ‍Announced results from co’s phase 2b randomized, double-blind, placebo-controlled study in patients with idiopathic pulmonary fibrosis​

* ‍Pamrevlumab was well tolerated with no safety risks identified during 48-week study​

* ‍Pamrevlumab in combination with either pirfenidone or nintedanib was not statistically significantly better than Pamrevlumab monotherapy​

* ‍Pamrevlumab met primary endpoint of FVC pct predicted with statistical significance, as well as absolute FVC volume​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below